Key facts
- Notable investors include Life Science Factory, Life Science Valley Ventures Management.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for brainQr Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for brainQr Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About brainQr Therapeutics
Developer of next-generation therapies designed to treat major human diseases by targeting disordered proteins. The company uses scientific innovation to pioneer novel treatment strategies that address urgent unmet medical needs, focusing on harnessing new approaches to modulate protein dysfunction implicated in a range of serious conditions, enabling patients to seek advanced, evidence-based rehabilitation options.
- Sector
- Healthcare
- HQ
- Göttingen, Germany
- Founded
- 2024
- Website
- brainqrtherapeutics.com/
- Ownership
- Privately Held (backing)
brainQr Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in brainQr Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on brainQr Therapeutics in its N-PORT filings yet. We sweep new filings monthly.